行情

XENT

XENT

Intersect ENT
NASDAQ

实时行情|Nasdaq Last Sale

21.45
+0.36
+1.71%
交易中 14:33 11/19 EST
开盘
21.14
昨收
21.09
最高
21.50
最低
21.14
成交量
7.46万
成交额
--
52周最高
35.87
52周最低
14.62
市值
6.76亿
市盈率(TTM)
-16.6952
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XENT 新闻

  • Edited Transcript of XENT earnings conference call or presentation 1-Nov-19 12:00pm GMT
  • Thomson Reuters StreetEvents.6天前
  • The Chief Commercial Officer of Intersect ENT, Inc. (NASDAQ:XENT), Robert Binney, Just Sold 100% Of Their Holding
  • Simply Wall St..11/12 13:58
  • Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates
  • Zacks.11/04 14:53
  • Intersect ENT, Inc. (XENT) CEO Tom West on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/01 17:34

更多

所属板块

医疗设备、用品及经销
+0.80%
医疗设备和用品
+1.11%

热门股票

名称
价格
涨跌幅

XENT 简况

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
展开

Webull提供Intersect ENT Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。